A recent study has shown that the experimental antiviral drug Obeldesivir successfully cured Ebola-infected monkeys, offering hope for human treatment. In the study, ten monkeys received a daily Obeldesivir pill starting one day after exposure to the Ebola virus, resulting in an 80% survival rate for cynomolgus macaques and 100% for rhesus macaques.

This promising outcome suggests Obeldesivir could be a practical and affordable treatment for Ebola in humans, pending further research and clinical trials.

Currently, Ebola treatments include monoclonal antibodies like ZMapp and ansuvimab. ZMapp is a combination of three chimeric monoclonal antibodies effective in Ebola-infected monkeys, though its efficacy in humans has not been conclusively demonstrated.

Ansuvimab, derived from an Ebola survivor's blood, has shown success in lowering mortality rates in clinical trials.

The development of Obeldesivir as an oral antiviral pill could provide a more practical and accessible treatment option compared to these antibody-based therapies.

Further studies are needed to confirm Obeldesivir's safety and effectiveness in humans before it can be approved for widespread use.